Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiovascular Risk Factor
Cardiovascular Diseases
Cardiovascular Stroke
Hypercholesterolemia

Interventions

DRUG: lerodalcibep
OTHER: Placebo

Sponsor

LIB Therapeutics LLC

Collaborators

[object Object]